Neurent Medical raises €62.5m Series C to expand NEUROMARK chronic rhinitis device globally

Galway-headquartered medtech company Neurent Medical has secured €62.5 million ($74 million) in an oversubscribed Series C financing round, providing the capital needed to accelerate commercial rollout of its flagship NEUROMARK system for the treatment of chronic rhinitis.

According to Medical Product Outsourcing, the round was led by MVM Partners, with Sofinnova Partners joining as a new investor alongside existing backers EQT Life Sciences, Atlantic Bridge and Fountain Healthcare Partners. Both MVM Partners and Sofinnova Partners will join Neurent Medical's Board of Directors through their respective partners Kyle Dempsey and Cedric Moreau.

Chronic rhinitis affects millions of people worldwide, producing persistent nasal congestion, rhinorrhea, sneezing and postnasal drip that can materially reduce quality of life. NEUROMARK addresses the condition at its root cause by targeting the overactive posterior nasal nerves responsible for driving symptoms, using Neurent's proprietary Impedance Controlled Radiofrequency technology to deliver minimally invasive, durable relief with a strong safety profile.

CEO Brian Shields said the financing would extend both commercial reach and clinical evidence generation. "This Series C financing will support our commercial expansion and help bring NEUROMARK to the patients and physicians who need it most. In addition to expanding patient access, this investment will also enable further evidence generation across broader populations and support the continued development of our exciting pipeline offerings."

Dempsey said Neurent had established a differentiated position within a rapidly growing treatment category. "In this rapidly emerging category, Neurent has set a new standard with a best-in-class solution, powered by a proprietary impedance control system that delivers real-time feedback, giving clinicians greater treatment confidence, control, and predictability during every procedure."

Moreau pointed to the platform's potential beyond its current indication. "We also see significant potential to expand this platform into additional indications, and we are confident in our partnership with Neurent Medical at this pivotal stage of commercial growth."

Neurent Medical maintains US operations in Braintree, Massachusetts, alongside its Galway headquarters.

Explore the full financing announcement in the complete report.